ArticleEuropean heart journal open2023
Safety of cangrelor and transition to oral P2Y
Article in European heart journal open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 26 citations in OpenAlex.
- Editorial comment: Periprocedural antiplatelet therapy during mechanical thrombectomy: navigating limited evidence.European stroke journal · 2026Article
- Oral P2YInternational journal of cardiology. Heart & vasculature · 2026Article
- In vitro and ex vivo Pharmacological Profile of HY-022619, a Novel Intravenous P2YPharmaceutical research · 2026Article
- Use of Cangrelor in Türkiye: A Multicenter Real-Life Study.Journal of clinical medicine · 2025Article
- Antiplatelet therapy in acute myocardial infarction complicated by cardiogenic shock.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Review
- The role of cangrelor in acute and high-risk PCI settings.European heart journal. Cardiovascular pharmacotherapy · 2025Review
- Pharmacodynamic effects of cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII Registry.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Observational
- Phenotyping the Use of Cangrelor in Percutaneous Coronary Interventions.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Cangrelor in Patients Undergoing Percutaneous Coronary Intervention After Out-of-Hospital Cardiac Arrest.Journal of clinical medicine · 2024Article
- Antiplatelet Therapy for Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Cangrelor is the only intravenous P2Y Methods and results: Adult patients with ACS undergoing percutaneous coronary intervention (PCI) receiving cangrelor were included in the study. Patients were followed for 30 days. Incidence of bleeding events, major adverse cardiac events, and transition strategy to oral P2Y Conclusion: The use of cangrelor in ACS patients undergoing PCI and the transition strategy to P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.